Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
EBITDA fell 26.7% year on year to Rs 1,388 crore from Rs 1,895 crore. The EBITDA margin contracted to 18.7% from 25% a year earlier, although it expanded 200 basis points sequentially.
Profit before tax stood at Rs 1,177 crore in Q2 FY27, down 36.5% year on year from Rs 1,854 crore.
Total expenses increased 5.64% year on year to Rs 6,016 crore from Rs 5,695 crore. Material costs rose 5.44% to Rs 2,634 crore from Rs 2,498 crore, while employee benefits expense increased 12.17% to Rs 1,475 crore from Rs 1,315 crore. Depreciation, impairment and amortisation expense climbed 16.16% to Rs 345 crore from Rs 297 crore.
Cipla's India business revenue increased 12% year on year to Rs 3,516 crore. North America revenue declined 19% to Rs 1,643 crore, while One Africa revenue fell 1% to Rs 1,171 crore. Emerging Markets and Europe revenue remained flat at Rs 967 crore, while API and Others revenue dropped 59% to Rs 107 crore.
Research and development expenditure stood at Rs 423 crore, equivalent to 5.7% of sales. The company reported a net cash position of Rs 9,823 crore.
Cipla managing director and global CEO Achin Gupta said the company continued to make progress across its focus markets. He noted that the India business delivered 12% year-on-year growth, while the US business recorded quarterly revenue of $172 million. The company expects its upcoming product pipeline to support performance in North America.
Cipla is a global pharmaceutical company focused on complex generics and expanding its presence in India, South Africa, North America and other regulated and emerging markets. Its portfolio includes respiratory, anti-retroviral, urology, cardiology, anti-infective and central nervous system products. The company operates 46 manufacturing sites, producing more than 1,500 products across over 50 dosage forms and serving more than 80 markets worldwide.
Cipla Ltd fell for a fifth straight session today. The stock is quoting at Rs 1336, down 0.6% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is up around 0.25% on the day, quoting at 22478.35. The Sensex is at 72073.15, up 0.23%.Cipla Ltd has eased around 4.23% in last one month.Meanwhile, Nifty Pharma index of which Cipla Ltd is a constituent, has eased around 2.14% in last one month and is currently quoting at 26311.55, down 0.79% on the day. The volume in the stock stood at 6.16 lakh shares today, compared to the daily average of 10.08 lakh shares in last one month.
The benchmark October futures contract for the stock is quoting at Rs 1335.2, down 1.24% on the day. Cipla Ltd tumbled 11.7% in last one year as compared to a 10.37% slide in NIFTY and a 19.85% spurt in the Nifty Pharma index.
The PE of the stock is 33.18 based on TTM earnings ending June 26.
Consequently, the issued, subscribed and paid-up share capital of the Company stands increased to Rs 1,61,57,41,230 comprising of 80,78,70,615 equity shares of face value Rs 2 each.
Invagen Pharmaceuticals Inc, a wholly owned subsidiary of Cipla announced that it has entered into a strategic partnership with Qilu Pharmaceutical Co. (Qilu), for the exclusive licensing and supply of QL2107, a biosimilar to Keytruda® (pembrolizumab), for the United States.
As part of the agreement, Qilu will be responsible for development, regulatory registration and supply of the product while Cipla USA Inc. will be responsible for the commercialization of the asset by leveraging its strong commercial presence in the defined territory. The collaboration reflects both companies' shared commitment to addressing the growing burden of cancer and improving access to advanced biologic therapies.
Qilu Pharmaceutical is now one of the leading vertically integrated pharmaceutical companies in China that develops, manufactures and distributes both finished dosage forms (FDFs) and active pharmaceutical ingredients (APIs).
As part of the agreement, Qilu will be responsible for development, regulatory registration and supply of the product while Cipla USA Inc. will be responsible for the commercialization of the asset by leveraging its strong commercial presence in the defined territory.
Achin Gupta, managing director & global chief executive officer, Cipla, said, “This partnership reflects Cipla’s confidence in the long-term potential of biosimilars and supports our strategy to build a strong oncology-focused portfolio.
By combining Qilu’s development strengths with Cipla’s commercial presence and patient-centric legacy, we aim to expand access to high-quality biologics for patients across our focus markets.'
Cipla is a global pharmaceutical company with operations across India, South Africa, North America and other regulated and emerging markets. The company focuses on complex generics and therapies including respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments. Cipla operates 46 manufacturing facilities globally, producing more than 1,500 products across over 80 markets.
The company’s consolidated net profit declined 39.19% to Rs 789.05 crore in Q1 FY27, compared with Rs 1,297.62 crore posted in Q1 FY26. Revenue from operations increased 3.51% YoY to Rs 7,077.02 crore in the quarter ended 30th June 2026.
The scrip shed 0.58% to currently trade at Rs 1380.90 on the BSE.
Under this agreement, Cipla will receive exclusive rights to develop and commercialise Rolditamig Deuderuxtecan, also known as TQB2102, in India, South Africa and 5 other emerging markets.
Cipla will be responsible for local clinical development, regulatory activities, and commercialisation in the licensed territories, while CTTQ will continue to manufacture and supply TQB2102.
Chia Tai Tianqing Pharmaceutical Group Co. is a subsidiary of Sino Biopharmaceutical (SBP Group).
TQB2102 is being evaluated across HER2-expressing cancers and has demonstrated encouraging clinical potential in HER2-low advanced breast cancer.
The collaboration brings together SBP Group’s differentiated late-stage oncology asset and development and manufacturing capabilities with Cipla’s established regulatory, medical, market access and commercial presence across India, South Africa, and other emerging markets.
The partnership is intended to accelerate local development and regulatory approvals, enabling patient access across licensed countries, subject to applicable approvals.
Achin Gupta, managing director and global chief executive officer, Cipla said: 'Breast cancer remains a significant healthcare challenge, and this agreement strengthens our oncology portfolio with a promising HER2-targeted antibody-drug conjugate.
Through our partnership with SBP Group and CTTQ, we aim to accelerate development and, subject to regulatory approvals, expand access to this innovative treatment across licensed territories.'
The scrip shed 0.10% to currently trade at Rs 1414.60 on the BSE.
Cipla and Sino Biopharmaceutical (HKEX: 1177) (SBP Group) today announced that SBP Group's subsidiary, Chia Tai Tianqing Pharmaceutical Group Co. (CTTQ), has entered into an exclusive license and supply agreement with Cipla for Rolditamig Deuderuxtecan, also known as TQB2102, a potential best-in-class HER2 bispecific antibody-drug conjugate (ADC).
Under this agreement, Cipla will receive exclusive rights to develop and commercialise TQB2102 in India, South Africa and 5 other emerging markets.
The collaboration brings together SBP Group's differentiated late-stage oncology asset and development and manufacturing capabilities with Cipla's established regulatory, medical, market access and commercial presence across India, South Africa, and other emerging markets.